Membership Directory

Antisoma

Category: Drug Development
Phone: 617-225-0522
Fax: 617-225-0525
Website: http://www.antisoma.com

Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer. Following the acquisition of Cambridge, MA-based Xanthus Pharmaceuticals, Inc. in June 2008, the Company has operations in the UK and Cambridge. Antisoma has seven drugs in cancer clinical trials. Key among these is ASA404, a tumor-vascular disrupting agent. A randomized phase II trial showed a 5-month survival benefit when ASA404 was added to standard chemotherapy for non-small cell lung cancer. Phase III development is now ongoing. In April 2007, Antisoma licensed ASA404 to Novartis in a global agreement worth up to $890 million in milestone payments plus royalties on sales. Antisoma also has an option to co-commercialize ASA404 with Novartis in the United States. Also in phase III development is AS1413, formerly Xanafide, which is being tested as a potential treatment for secondary AML.

Back to list

Recent Jobs